Lake Hills Wealth Management LLC Purchases 914 Shares of Eli Lilly and Company $LLY

Lake Hills Wealth Management LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 914 shares of the company’s stock, valued at approximately $1,058,000.

Several other hedge funds also recently added to or reduced their stakes in LLY. Worth Asset Management LLC raised its stake in Eli Lilly and Company by 9.4% in the third quarter. Worth Asset Management LLC now owns 1,786 shares of the company’s stock valued at $2,067,000 after buying an additional 153 shares during the last quarter. Matrix Trust Co increased its holdings in shares of Eli Lilly and Company by 10.4% during the third quarter. Matrix Trust Co now owns 2,931 shares of the company’s stock valued at $3,391,000 after acquiring an additional 275 shares in the last quarter. Crumly & Associates Inc. increased its holdings in shares of Eli Lilly and Company by 11.2% during the third quarter. Crumly & Associates Inc. now owns 882 shares of the company’s stock valued at $1,021,000 after acquiring an additional 89 shares in the last quarter. Weaver Consulting Group raised its position in shares of Eli Lilly and Company by 32.1% in the 3rd quarter. Weaver Consulting Group now owns 728 shares of the company’s stock valued at $842,000 after purchasing an additional 177 shares during the last quarter. Finally, Nautilus Advisors LLC raised its position in shares of Eli Lilly and Company by 9.3% in the 3rd quarter. Nautilus Advisors LLC now owns 555 shares of the company’s stock valued at $642,000 after purchasing an additional 47 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $39.91 during trading hours on Wednesday, reaching $1,197.40. The company had a trading volume of 1,223,772 shares, compared to its average volume of 2,968,354. The business’s 50 day moving average price is $1,173.98 and its 200-day moving average price is $1,092.69. The firm has a market cap of $1.13 trillion, a PE ratio of 40.20, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts forecast that Eli Lilly and Company will post 36.66 EPS for the current year.

Wall Street Analyst Weigh In

LLY has been the topic of several research analyst reports. Sanford C. Bernstein boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research note on Friday, August 7th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, August 26th. Jefferies Financial Group upped their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Finally, JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,312.36.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong GLP-1 growth outlook: Analysts remain constructive on Lilly’s Mounjaro and Zepbound franchises, while anticipated momentum from the oral GLP-1 candidate Foundayo could support growth in the second half of 2026. Recent data presented at a diabetes meeting showed Foundayo produced greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes, although commercial and regulatory execution remain important. Eli Lilly’s Breakout May Occur Soon – H2’26 Foundayo Tailwinds
• Positive Sentiment: Pipeline diversification: Lilly is working to reduce reliance on obesity and diabetes products through oncology, immunology, neuroscience, and other areas. The FDA granted orphan-drug designation to experimental cancer treatment olomorasib, providing potential development incentives and exclusivity benefits. Lilly also expanded its drug-discovery collaboration with Gate Bioscience in a deal potentially worth more than $870 million. Eli Lilly Stock Gains on Regulatory Win
• Positive Sentiment: Additional development progress: Early-stage updates for elt­re­kibart and a new basal-insulin candidate point to continued investment in Lilly’s pipeline. Its partnership with insitro is also making machine-learning tools available through Lilly TuneLab, potentially improving external drug discovery and future licensing opportunities. Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone
• Neutral Sentiment: Upcoming earnings focus: Investor attention is building ahead of third-quarter results. Recent coverage points to improving operating momentum, but expectations are already high following the company’s prior revenue and earnings outperformance.
• Negative Sentiment: Valuation and concentration risks: Commentary warns that Lilly trades at a substantial premium to the broader market, leaving limited room for disappointing sales, pricing, or guidance. Falling U.S. prices for Zepbound and Mounjaro could also pressure future margins or growth assumptions. Eli Lilly: Impressive Growth, Questionable Valuation
• Negative Sentiment: Childhood-obesity guidance: New World Health Organization guidelines discourage certain approaches to treating childhood and adolescent obesity, creating potential uncertainty around how quickly GLP-1 therapies could expand in younger populations. WHO Childhood Obesity Guidelines

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.